Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality

被引：0
|
作者：
Merimsky, O. [1 ]
Shamai, S. [2 ]
机构：
[1] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[2] Tel Aviv Med Ctr & Sch Med, Oncol, Tel Aviv, Israel
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Daily Practice; Nivolumab; NSCLC;
D O I：
10.1016/j.jtho.2017.11.085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.07-026
引用
收藏
页码：S2425 / S2425
页数：1
相关论文
共 50 条
  • [1] Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Schmid, S.
    Diem, S.
    Krapf, M.
    Li, Q.
    Flatz, L.
    Leschka, S.
    Desbiolles, L.
    Klingbiel, D.
    Jochum, W.
    Fruh, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2419 - S2420
  • [2] Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)
    Bagley, Stephen
    Kothari, Shawn
    Aggarwal, Charu
    Bauml, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1289 - S1289
  • [3] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data
    Dudnik, Elizabeth
    Moskovitz, Mor
    Daher, Sameh
    Shamai, Sivan
    Hanovich, Ekaterina
    Shechtman, Yelena
    Abu-Amna, Mahmoud
    Zer, Alona
    Wollner, Mira
    Bar, Jair
    Merimsky, Ofer
    Cyjon, Arnold
    Shochat, Tzippy
    Peled, Nir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S417 - S418
  • [4] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): A Real-Life Study
    Reis, D.
    Mendes, A.
    China, N.
    Dias, M.
    Coutinho, D.
    Silva, E.
    Campainha, S.
    Costa, T.
    Conde, S.
    Barroso, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S975 - S976
  • [5] Advanced non-small cell Lung Cancer (NSCLC) Nivolumab in advanced NSCLC with Squamous Epithelial Histology
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 149 - 149
  • [6] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Nivolumab for treating non-small cell lung cancer
    Guibert, Nicolas
    Mazieres, Julien
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (12) : 1789 - 1797
  • [8] Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer
    Morgensztern, Daniel
    Herbst, Roy S.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3713 - 3717
  • [9] Perioperative Nivolumab in non-small cell Lung Cancer
    Lorenz, Judith
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (18) : 1065 - 1066
  • [10] Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
    Schmid, Sabine
    Diem, Stefan
    Li, Qiyu
    Krapf, Mirjam
    Flatz, Lukas
    Leschka, Sebastian
    Desbiolles, Lotus
    Klingbiel, Dirk
    Jochum, Wolfram
    Fruh, Martin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (12) : 1825 - 1832
12345